Member Spotlight: Associate Professor Antony Vinh
Associate Professor Antony Vinh heads the Hypertension and Immunobiology Research Division at La Trobe University’s Centre for Cardiovascular Biology and Disease Research. With over two decades investigating hypertension’s underlying mechanisms, he has secured more than $6 million in funding and published 85 scientific works. His pioneering research into inflammation, immune activation, and gut microbiome dysbiosis earned him Hypertension Australia’s prestigious 2022 Jaye Chin-Dusting Outstanding Mid-Career Research Award.
What inspired your interest in Hypertension?
My interest in hypertension stems from its paradoxical position in global health: it is the leading risk factor for all-cause mortality worldwide, yet remains underappreciated outside the hypertension research community. For over two decades, I have been fascinated by how this seemingly silent condition drives a cascade of cardiovascular and non-cardiovascular pathologies—from heart failure and stroke to kidney disease and cognitive decline.
Despite its enormous burden, why does hypertension receive so little attention compared to other chronic diseases? Even more striking is that in approximately 90% of patients, we still do not know the precise mechanisms underlying its development. These unanswered questions have fueled my research program. Understanding the origins of hypertension is not merely an academic exercise; it is essential to mitigating the single greatest modifiable risk factor for mortality worldwide. My ultimate goal is to translate mechanistic insights into effective prevention and treatment strategies that can reduce the global impact of cardiovascular disease.
Tell us about your research or initiatives focused on preventing, detecting, and managing high blood pressure and its complications.
My research program focuses on identifying mechanistic drivers of hypertension to enable earlier detection and targeted prevention of its complications. Hypertension remains the leading risk factor for global mortality, yet in approximately 90% of cases, its origins are unknown.
At La Trobe University’s Centre for Cardiovascular Biology and Disease Research, I lead the Hypertension and Immunobiology Division, integrating vascular biology, immunology, and pharmacology to discover novel therapeutic targets. Our work has revealed that non-classical pathways—such as inflammation, immune activation, fibrosis, and gut microbiome dysbiosis—are major contributors to hypertension and related organ damage.
We have identified key mechanisms involving the NLRP3 inflammasome and its downstream cytokine interleukin-18 (IL-18), which drive vascular, cardiac, and renal pathology. These discoveries have led to partnerships with industry to develop IL-18-, inflammasome-, and NOX-targeting agents.
To achieve these insights, we employ several pre-clinical models of hypertension (angiotensin II infusion, DOCA-salt, metabolic syndrome) combined with advanced in vivo technologies such as radiotelemetry for continuous blood pressure monitoring, high-resolution ultrasound imaging for cardiac and vascular function, and transdermal GFR assessment for renal health. These models allow us to validate mechanistic targets and test novel pharmacological interventions.
Recent technological advances have transformed our approach. We use single-cell RNA sequencing and spatial transcriptomics to map the aortic cellulome during hypertension and identify fibrogenic drivers of aortic stiffening. Additionally, we apply metagenomic sequencing to characterise the gut virome, uncovering bacteriophages that disrupt protective bacterial communities and may represent new therapeutic targets. These cutting-edge tools enable us to define cellular and molecular signatures that precede overt hypertension, creating opportunities for predictive biomarkers and precision interventions.
Have you received any awards, grants, or publications for your work related to Hypertension?
Biometrics:
- 85 publications (75 journal articles, 10 book chapters)
- Google Scholar: 8,728 citations; H-index = 44, i10 index = 63
- SciVal field-weighted citation impact = 6.17 (2.43 across all subject areas)
- 70% of publications in Q1 journals
- Over $6 million in research funding secured
Fellowships, honours and awards:
- 2022: Hypertension Australia Jaye Chin-Dusting Outstanding Mid-Career Research Award
- 2013-2014: Heart Foundation Australia Postdoctoral Fellowship
- 2011-2012: Heart Foundation Australia Postdoctoral Fellowship
- 2011-2015: Monash University Larkins Fellowship
- 2011: NHMRC Overseas Biomedical Fellowship
- 2011: ASCEPT Denis Wade New Investigator Award
- 2010: American Heart Association (AHA) Postdoctoral Fellowship
- American Physiology Society: Wiggers Award – Cardiovascular Section representative
What do you enjoy doing in your free time?
Fishing, AFL (passionate Melbourne Demons supporter), basketball, volleyball, and watching the kids play sports and perform.
Do you have any travel adventures or bucket list destinations you're hoping to experience?
Iceland, Japan (visits annually), sabbaticals in Spain and Switzerland.
What's the last great book you read, movie you saw, or show you watched?
I am an Anime fan and enjoyed the series “Solo Levelling”.
Where can we find out more about your work with Hypertension?
https://www.latrobe.edu.au/research/centres/cardiovascular/research/hypertension-and-immunobiology